HOME > TOP STORIES

TOP STORIES

COMMENTARY Battle over Off-Year Price Revision Now Heading for Political Settlement

December 13, 2024
REGULATORY CDP OKs Bill to Scrap Off-Year Revisions, Aims for Diet Submission Soon

December 13, 2024
REGULATORY Hearing Leaves Chuikyo Mixed on Off-Year Scheme, Political Decision Ever More Likely

December 12, 2024
BUSINESS ViiV to Hone In on Long-Acting Treatments for HIV: Japan President

December 11, 2024
REGULATORY LDP Study Group Urges Health, Finance Ministers to Drop Off-Year Revisions

December 11, 2024
BUSINESS Off-Year Re-Pricing Will Ruin Investment Momentum: BMS Japan Chief

December 10, 2024
REGULATORY PM Ishiba Takes Note of Opposition Party’s Plea for Scrapping Off-Year Revisions

December 9, 2024
BUSINESS Generic Industry Shakeup Advances as Teva Takeda Joins JWP-Medipal Group

December 9, 2024
BUSINESS LEO Pharma Japan Set to Follow Global Growth as Stand-Alone Sales Force Matures

December 9, 2024
ACADEMIA Generic DPP-4s to Impact Diabetes Care and Health Finances, Potential Shortages a Concern

December 6, 2024
BUSINESS First Generics of Equa Priced at 30% of Original Product

December 6, 2024
REGULATORY Chuikyo Begins Debate on Scope of FY2025 Off-Year Drug Price Revisions

December 5, 2024
REGULATORY DPP Submits Request to MOF for Scrapping Off-Year Revisions

December 5, 2024
REGULATORY (Update) Average NHI-Market Price Gap Narrows to 5.2% to Hit Record Low

December 4, 2024
REGULATORY Opposition DPP Leader Pledges to Go Full Throttle on Ending Off-Year Revisions

December 3, 2024
REGULATORY Qalsody, Zepbound, Zeposia Inch Closer to Japan Approval with Panel OK

December 3, 2024
REGULATORY LDP Pharma Study Group Renews Call for Ditching Off-Year Revisions

December 3, 2024
BUSINESS Lilly Japan Pitching Unique Benefits of Kisunla with AD Drug Now on Market

December 2, 2024
REGULATORY Japan Cabinet OKs Extra Budget, 44 Billion Yen for Pharma Measures

December 2, 2024
REGULATORY MOF Panel Urges Annual Price Revisions on All Drugs in 2025 Budget Proposal

November 29, 2024

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Shift Underway in Pharma Workforce as Sales Roles Shrink, Manufacturing Rises

By Hayate Horiguchi

Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…